Search

Your search keyword '"Robaeys, G"' showing total 255 results

Search Constraints

Start Over You searched for: Author "Robaeys, G" Remove constraint Author: "Robaeys, G"
255 results on '"Robaeys, G"'

Search Results

1. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

2. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

4. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience

6. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference

12. The case for simplifying and using absolute targets for viral hepatitis elimination goals

13. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

14. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes

17. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium : an observational study

21. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium?

26. Horizontal hepatitis B virus transmission through non-sexual close contact in Turkish chronic hepatitis B patients living outside of Turkey

27. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

29. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

30. Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe

32. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience

36. Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection

37. Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse

39. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

40. Recommendations for the management of hepatitis C virus infection among people who inject drugs

41. EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY

44. Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs

45. P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study

46. A pilot observational survey of hepatitis C in Belgium

49. The epidemiology of hepatitis C among injecting drug users in Belgium

Catalog

Books, media, physical & digital resources